Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol
P. Racz, M. R. Ruzsonyi, Z. T. Nagy, Z. Gaygi and L. Z. Bito
Department of Ophthalmology, Markusovszky Hospital, Szombathely, Hungary.
OBJECTIVE: To determine whether once-daily, in the morning, topical
application of the new ocular hypotensive prostaglandin analogue,
latanoprost, yields nocturnal intraocular pressure (IOP) reduction similar
to its diurnal IOP reducing efficacy. STUDY DESIGN AND PATIENTS: Placebo-
controlled, randomized, and double-masked study on hospitalized patients
with ocular hypertension or glaucoma. Patients in group 1 (n=9) were
maintained on twice-daily applications of 0.5% timolol maleate. Patients in
group 2 (n=10) terminated their timolol treatment 3 weeks before the
beginning of the study. In both groups the test drug (0.005% latanoprost)
and its vehicle (placebo) was applied by hospital staff every morning for 9
days. MEASUREMENTS: After 4 days of ambulatory treatment, patients were
hospitalized, and IOP values were obtained in the supine and sitting
positions with a handheld electronic tonometer (Tono-Pen XL, Bio-Rad,
Glendale, Calif) and a Goldmann's applanation tonometer, covering every
2-hour interval, around the clock, but not more than at four time points
per day during a 5-day period. RESULTS: The mean nocturnal IOPs (Goldmann's
applanation tonometer) collected for 5 days were mean +/-SEM 17.9+/-0.6 vs
20.2+/-0.6 mm Hg and 16.8+/-0.3 vs 20.6+/-0.5 mm Hg for the study vs the
control eyes in group 1 and group 2, respectively. These nocturnal IOP
reductions were statistically significant (P<.001, two-tailed paired
Student's t test). The differences between diurnal and nocturnal IOP
reductions (handheld electronic or Goldmann's applanation tonometer) were
minimal (>0.3 mm Hg) and statistically not significant (P>.31,
two-tailed paired Student's t test). CONCLUSION: Once-daily latanoprost
treatment provides uniform circadian (around-the-clock) IOP reduction by
itself, or in combination with timolol.
Prostaglandin FP Receptors Do Not Contribute to 24-hour Intraocular Pressure Variation in Mice
Crowston et al.
IOVS 2007;48:2095-2098.
ABSTRACT
| FULL TEXT
Effects of Topical Hypotensive Drugs on Circadian IOP, Blood Pressure, and Calculated Diastolic Ocular Perfusion Pressure in Patients with Glaucoma.
Quaranta et al.
IOVS 2006;47:2917-2923.
ABSTRACT
| FULL TEXT
Crossover Comparison of Timolol and Latanoprost in Chronic Primary Angle-closure Glaucoma
Sihota et al.
Arch Ophthalmol 2004;122:185-189.
ABSTRACT
| FULL TEXT
The Effect of Latanoprost, Brimonidine, and a Fixed Combination of Timolol and Dorzolamide on Circadian Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension
Orzalesi et al.
Arch Ophthalmol 2003;121:453-457.
ABSTRACT
| FULL TEXT
Meta-analysis of randomised controlled trials comparing latanoprost with timolol in the treatment of patients with open angle glaucoma or ocular hypertension
Zhang et al.
Br. J. Ophthalmol. 2001;85:983-990.
ABSTRACT
| FULL TEXT
A New Approach to the Medical Management of Glaucoma, from the Bench to the Clinic, and Beyond: The Proctor Lecture
Bito
IOVS 2001;42:1126-1133.
FULL TEXT
Effect of Timolol, Latanoprost, and Dorzolamide on Circadian IOP in Glaucoma or Ocular Hypertension
Orzalesi et al.
IOVS 2000;41:2566-2573.
ABSTRACT
| FULL TEXT
Effect of latanoprost on intraocular pressure in patients with glaucoma on maximal tolerated medical treatment
AZUARA-BLANCO et al.
Br. J. Ophthalmol. 1997;81:1115b-1115.
FULL TEXT